FIBROGEN Forum: Community User: NOK

was ist den hier los? nichts? sollte schon einmal steigen.

https://www.globenewswire.com/news-release/2021/08/25/2286187/33525/en/FibroGen-Announces-Positive-Topline-Results-from-Phase-2-Clinical-Trial-of-Roxadustat-for-the-Treatment-of-Chemotherapy-Induced-Anemia.html

FibroGen's Roxadustat Aces Chemo-Induced Anemia Trial https://www.benzinga.com/general/biotech/21/08/22654151/fibrogens-roxadustat-aces-chemo-induced-anemia-trial

bin hier auch investiert und hatte schon meine Zweifel....

Super!!!!!

$FGEN Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

FibroGen (FGEN) Receives CRL from FDA for Roxadustat for Anemia of Chronic Kidney Disease https://www.streetinsider.com/dr/news.php?id=18800521&gfv=1 ... The letter indicates the FDA will not approve the roxadustat NDA in its present form and has requested additional clinical study of roxadustat be conducted, prior to resubmission. ...

FibroGen Reports Second Quarter 2021 Financial Results https://www.globenewswire.com/news-release/2021/08/09/2277395/33525/en/FibroGen-Reports-Second-Quarter-2021-Financial-Results.html • Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis. • Total roxadustat net sales in China of $52.8 million1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca • Roxadustat Receives Positive Opinion from the CHMP of EMA for Patients with Anemia of CKD • Roxadustat Receives Negative Vote from FDA Advisory Committee for Patients with Anemia of CKD ...

Guter Zeitpunkt um einzusteigen. Kursziele hier: https://ch.marketscreener.com/kurs/aktie/FIBROGEN-INC-18537026/analystenerwartungen/

Eluminex Biosciences Licenses Investigational Biosynthetic Cornea from FibroGen https://www.marketwatch.com/story/eluminex-biosciences-licenses-investigational-biosynthetic-cornea-from-fibrogen-271626695741

Ich warte noch.....

Sie tut gerade alles dafür 📉

Fibrogen hat Potenzial ohne Ende

Noch bisschen tiefer, dann bin ich sofort wieder dabei

AstraZeneca, FibroGen hit another roxadustat setback as FDA panel calls for more safety data https://www.fiercepharma.com/pharma/astrazeneca-fibrogen-hit-another-roxadustat-setback-as-fda-panel-calls-for-more-safety-data